Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF
  • Original article
  • Open access
  • Published:

Expression of the leukocyte-associated Ig-like receptor-1 on B lymphocytes from systemic lupus erythematosus patients

Egyptian Rheumatology and Rehabilitation volume 43, pages 124–130 (2016)Cite this article

Abstract

Background

The leukocyte-associated immunoglobulin (Ig)-like receptor-1 (LAIR-1) is a transmembrane molecule belonging to the Ig superfamily. In B cells, LAIR-1 cross-linking leads to downregulation of Ig and cytokine production.

Aim of the work

The aim of the present study was to assess the expression of LAIR-1 on peripheral blood B lymphocyte from systemic lupus erythematosus (SLE) patients, and its correlation with disease manifestations.

Patients and methods

Twenty-two SLE female patients and 16 matched healthy controls were included in the study. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score was assessed. The expression of LAIR-1 was determined by using flow cytometry.

Results

The 22 SLE patients had a mean age of 25.59±4.22 years and disease duration of 5–24 months. The mean SLEDAI was 8±1.5. The percentage of CD19+ B lymphocytes lacking LAIR-1 was markedly increased in SLE patients (27.8 ±10.9%) compared with healthy controls (16.2±4.4%) (P<0.001). The mean fluorescent intensity ratio (MFIR) of LAIR-1 expression on CD19+ B cells was strongly decreased in SLE patients (44.1±12.6) compared with healthy controls (58.9±7.7) (P<0.001). The percentage of CD19+ LAIR-1− B cells significantly correlated with the complement (C4) (r=0.45, P=0.03) and the serum creatinine level (r=0.47, P=0.02), and negatively with the serum albumin level (r=−0.57, P=0.005). The MFIR of LAIR-1 significantly correlated with the serum albumin level (r=0.74, P<0.001) and negatively correlated with the serum creatinine level (r=−0.43, P=0.041). There was no significant association of LAIR− (%) or the MFIR with the clinical manifestations of the patients.

Conclusion

This study points out that the lack of LAIR-1 expression on B cells from SLE patients could be a trigger for the dysregulation of antibody production in SLE, and is associated with the degree of renal affection as evidenced by the significant correlation with serum creatinine levels and negative correlation with the levels of serum albumin.

References

  1. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008; 83:799–803.

    Article  CAS  PubMed  Google Scholar 

  2. Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci USA 2012; 109:E3160–E3167.

    Article  CAS  PubMed  Google Scholar 

  3. van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur J Immunol 1999; 29:3160–3167.

    Article  PubMed  Google Scholar 

  4. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929–39.

    Article  CAS  PubMed  Google Scholar 

  5. La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther 2010; 10:1555–1561.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:326–337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Paran D, Naparstek Y, Is B. Cell-targeted therapy effective in systemic lupus erythematosus?. Isr Med Assoc J 2015; 17:98–103.

    PubMed  Google Scholar 

  8. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies: before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526–1530.

    Article  CAS  PubMed  Google Scholar 

  9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40:1725.

    Article  CAS  PubMed  Google Scholar 

  10. Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23:S120–S132.

    CAS  PubMed  Google Scholar 

  11. Daëron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosinebased inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224:11–43.

    Article  PubMed  Google Scholar 

  12. Tang X, Tian L, Esteso G, Choi SC, Barrow AD, Colonna M, et al. Leukocyte-associated Ig-like receptor-1-deficient mice have an altered immune cell phenotype. J Immunol 2012; 188:548–558.

    Article  CAS  PubMed  Google Scholar 

  13. Youinou P, Renaudineau Y. CD5 expression in B cells from patients with systemic lupus erythematosus. Crit Rev Immunol 2011; 31:31–42.

    Article  CAS  PubMed  Google Scholar 

  14. Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis 2011; 70:i64–i66.

    Article  CAS  PubMed  Google Scholar 

  15. Sestak AL, Fürnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011; 70:i37–i43.

    Article  CAS  PubMed  Google Scholar 

  16. Gayed M, Gordon C. Novel treatments for systemic lupus erythematosus. Curr Opin Investig Drugs 2010; 11:1256–1264.

    CAS  PubMed  Google Scholar 

  17. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10:55–60.

    Article  CAS  PubMed  Google Scholar 

  18. Colombo BM, Canevali P, Magnani O, Rossi E, Puppo F, Zocchi MR, et al. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients. PLoS One 2012; 7:e31903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kanakoudi-Tsakalidou F, Farmaki E, Tzimouli V, Taparkou A, Paterakis G, Trachana M, et al. Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options?.. Lupus 2014; 23:305–312.

    CAS  PubMed  Google Scholar 

  20. Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, et al. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica 2014; 99:881–887.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008; 22:980–988.

    Article  CAS  PubMed  Google Scholar 

  22. Huang ML, Li CG, Wang GB, Zu Y. Expression of leukocyte-associated Iglike receptor-1 in children with immune thrombocytopenia. Zhongguo Dang Dai Er Ke Za Zhi 2014; 16:370–374.

    CAS  PubMed  Google Scholar 

  23. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 2011; 186:4223–4233.

    Article  CAS  PubMed  Google Scholar 

  24. Poggi A, Pellegatta F, Leone BE, Moretta L, Zocchi MR. Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol 2000; 30:2751–2758.

    Article  CAS  PubMed  Google Scholar 

  25. Zocchi MR, Pellegatta F, Pierri I, Gobbi M, Poggi A. Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factordependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells. Eur J Immunol 2001; 31:3667–3675.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Menoufia University, Menofia Governorate, Yassin Abd Al-Ghafar St. off Gamal Abd Al-Naser St. Shebin Alkom, Menoufia, 32111, Egypt

    Heba A. Esaily MD

  2. Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menofia Governorate, Egypt

    Wafaa M. Radwan

  3. Department of Internal Medicine, Faculty of Medicine, Menoufia University, Menofia Governorate, Egypt

    Hany S. Elbarbary

  4. Department of Community Medicine and Public Health, Faculty of Medicine, Menoufia University, Menofia Governorate, Egypt

    Azza A. Taha

Authors
  1. Heba A. Esaily MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wafaa M. Radwan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hany S. Elbarbary
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Azza A. Taha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heba A. Esaily MD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esaily, H.A., Radwan, W.M., Elbarbary, H.S. et al. Expression of the leukocyte-associated Ig-like receptor-1 on B lymphocytes from systemic lupus erythematosus patients. Egypt Rheumatol Rehabil 43, 124–130 (2016). https://doi.org/10.4103/1110-161X.189821

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-161X.189821

Keywords